Skip to main content
. Author manuscript; available in PMC: 2013 May 13.
Published in final edited form as: Cancer. 2008 Apr 15;112(8):1754–1764. doi: 10.1002/cncr.23327

TABLE 2.

Patient Characteristics

Factor at first transplant Overall no. with factor/no. with valid data for factor (%) Treatment group: No. of patients/total no. (%)
P
Nonprotocol Other protocol TT protocols 1, 2, 3
Women 1157/3075 (38) 334/894 (37) 401/1103 (36) 422/1078 (39) .397
White 2744/3074 (89) 787/894 (88) 995/1102 (90) 962/1078 (89) .269
Age ≥65 y 689/3077 (22) 248/895 (28) 229/1104 (21) 212/1078 (20) <.001
IgA subtype 557/2634 (21) 124/610 (20) 194/971 (20) 239/1053 (23) .279
K light chain 1649/2555 (65) 371/590 (63) 632/942 (67) 646/1023 (63) .119
Hemoglobin <10 g/dL 942/2884 (33) 322/829 (39) 366/989 (37) 254/1066 (24) <.001
Platelets <100,000/mL 354/2884 (12) 174/829 (21) 102/989 (10) 78/1066 (7) <.001
Creatinine ≥1.5 mg/dL 414/2883 (14) 175/829 (21) 152/989 (15) 87/1065 (8) <.001
Albumin <3.0 g/dL 263/2881 (9) 123/830 (15) 110/986 (11) 30/1065 (3) <.001
CRP ≥6.0 mg/L 1091/2776 (39) 333/800 (42) 412/942 (44) 346/1034 (33) <.001
B2M ≥3.0 mg/L 986/2810 (35) 345/799 (43) 351/968 (36) 290/1043 (28) <.001
LDH ≥190 U/L 811/2877 (28) 248/827 (30) 259/986 (26) 304/1064 (29) .202
Cytogenetic abnormality 1085/3016 (36) 337/863 (39) 368/1078 (34) 380/1075 (35) .070
 CA13/hypodiploidy 733/3016 (24) 248/863 (29) 239/1078 (22) 246/1075 (23) .001
CR prior to first transplant 335/2774 (12) 62/795 (8) 96/942 (10) 177/1037 (17) <.001
First transplant within 6 mo of first therapy 1939/3004 (65) 581/852 (68) 691/1099 (63) 667/1053 (63) .031
Completed 2 transplants 2178/3077 (71) 504/895 (56) 779/1104 (71) 895/1078 (83) <.001
Time interval <6 mo to second transplant 1858/2178 (85) 407/504 (81) 613/779 (79) 838/895 (94) <.001
Post-transplantation CR 1520/2967 (51) 378/861 (44) 489/1058 (46) 653/1048 (62) <.001

TT indicates Total Therapy; IgA, immunoglobulin A; CRP, C-reactive protein; B2M, β-2-microglobulin; LDH, lactate dehydrogenase; CA, cytogenetic abnormality; CR, complete response.